SCHEMBL14427284

SCHEMBL14427284

CCOc1ccc(Oc2ccc(S(=O)(=O)N3CCc4ccccc4[C@@H]3C(=O)O)cn2)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MMP1 P03956 5/20 0.51
▸ MMP2 P08253 4/20 0.44
▸ MMP14 P50281 4/20 0.44
▸ MMP7 P09237 3/20 0.44
▸ MMP9 P14780 3/20 0.44
▸ MMP12 P39900 3/20 0.44
▸ MMP15 P51511 3/20 0.44
▸ MMP16 P51512 3/20 0.44
▸ MMP26 Q9NRE1 3/20 0.44
▸ AKR1C3 P42330 1/20 0.41
▸ ALOX5 P09917 1/20 0.41
▸ ADAMTS4 O75173 1/20 0.41
▸ MMP13 P45452 1/20 0.41
▸ ADAMTS5 Q9UNA0 1/20 0.41
▸ USP2 O75604 1/20 0.41
▸ POLB P06746 1/20 0.41
▸ LMNA P02545 2/20 0.41
▸ HDAC1 Q13547 1/20 0.40
▸ HDAC2 Q92769 1/20 0.40
▸ HDAC8 Q9BY41 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14427164 0.92 MMP1 (0.47) MMP1MMP2MMP14MMP7MMP9
SCHEMBL14427277 0.91 MMP1 (0.51) MMP1MMP2MMP14MMP7MMP9
SCHEMBL14427281 0.91 MMP1 (0.64) MMP1MMP2MMP14MMP7MMP9
SCHEMBL14427269 0.89 MMP1 (0.44) MMP1MMP2MMP14MMP7MMP9
SCHEMBL14427283 0.89 MMP1 (0.46) MMP1MMP2MMP14MMP7MMP9
SCHEMBL14427256 0.89 MMP1 (0.46) MMP1MMP2MMP14MMP7MMP9
SCHEMBL14427260 0.89 MMP1 (0.48) MMP1MMP2MMP14MMP7MMP9
SCHEMBL14427264 0.87 MMP1 (0.47) MMP1MMP2MMP14MMP7MMP9
SCHEMBL14427266 0.87 MMP1 (0.47) MMP1MMP2MMP14MMP7MMP9
SCHEMBL14427279 0.87 MMP1 (0.44) MMP1MMP2MMP14MMP7MMP9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070203118-A1 SUBSTITUTED TETRAHYDROISOQUINOLINES USED IN THE FORM OF MMP INHIBITORS, METHOD FOR THE PRODUCTION AND USE THEREOF IN THE FORM OF DRUGS SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2007-08-30 — — US disclosed
US-20070203118-A1 SUBSTITUTED TETRAHYDROISOQUINOLINES USED IN THE FORM OF MMP INHIBITORS, METHOD FOR THE PRODUCTION AND USE THEREOF IN THE FORM OF DRUGS SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2007-08-30 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070203118-A1 SUBSTITUTED TETRAHYDROISOQUINOLINES USED IN THE FORM OF MMP INHIBITORS, METHOD FOR THE PRODUCTION AND USE THEREOF IN THE FORM OF DRUGS MMP9, MMP2, MMP3 MMP1 8/4885MMP2 2/4885MMP14 12/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback